TRCT
CCCC icon

Tower Research Capital (TRC)’s C4 Therapeutics CCCC Stock Holding History

Tower Research Capital (TRC)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.9K Sell
9,849
-16,131
-62% -$38K ﹤0.01% 3296
2025
Q4 		$49.6K Buy
25,980
+17,566
+209% +$41.6K ﹤0.01% 2418
2025
Q3 		$18.7K Sell
8,414
-32,178
-79% -$77.2K ﹤0.01% 3371
2025
Q2 		$58K Buy
40,592
+33,317
+458% +$48.5K ﹤0.01% 2839
2025
Q1 		$11.6K Sell
7,275
-3,699
-34% -$11K ﹤0.01% 3520
2024
Q4 		$39.5K Sell
10,974
-12,722
-54% -$63.3K ﹤0.01% 2710
2024
Q3 		$135K Buy
23,696
+1,852
+8% +$11.1K ﹤0.01% 1990
2024
Q2 		$101K Buy
21,844
+14,931
+216% +$89K ﹤0.01% 2574
2024
Q1 		$56.5K Sell
6,913
-9,409
-58% -$72.9K ﹤0.01% 2190
2023
Q4 		$92.2K Buy
16,322
+4,063
+33% +$9.26K ﹤0.01% 2711
2023
Q3 		$22.8K Buy
12,259
+2,877
+31% +$8.78K ﹤0.01% 3259
2023
Q2 		$25.8K Buy
9,382
+5,546
+145% +$17.8K ﹤0.01% 3163
2023
Q1 		$12K Buy
3,836
+2,339
+156% +$13.8K ﹤0.01% 4055
2022
Q4 		$9K Sell
1,497
-8,603
-85% -$71.3K ﹤0.01% 4168
2022
Q3 		$89K Buy
10,100
+7,268
+257% +$75.5K ﹤0.01% 2655
2022
Q2 		$21K Sell
2,832
-8,204
-74% -$72.2K ﹤0.01% 3729
2022
Q1 		$268K Buy
11,036
+6,209
+129% +$151K ﹤0.01% 1529
2021
Q4 		$155K Buy
4,827
+2,003
+71% +$79.2K ﹤0.01% 1950
2021
Q3 		$126K Buy
2,824
+1,680
+147% +$71.9K ﹤0.01% 2202
2021
Q2 		$44K Sell
1,144
-932
-45% -$33.4K ﹤0.01% 3122
2021
Q1 		$76K Buy
2,076
+1,790
+626% +$71.2K ﹤0.01% 2793
2020
Q4 		$9K Buy
+286
New +$8.29K ﹤0.01% 4372

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tower Research Capital (TRC)'s CCCC Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its C4 Therapeutics (CCCC) stake by 62% in Q1 2026, selling an estimated $38K and leaving 9,849 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3296.

Tower Research Capital (TRC) first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $268K in Q1 2022. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Tower Research Capital (TRC) held 9,849 shares of C4 Therapeutics worth $25.9K as of Q1 2026.
  • Tower Research Capital (TRC) sold 16,131 C4 Therapeutics shares in Q1 2026, an estimated $38K.
  • C4 Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3296 holding.
  • Tower Research Capital (TRC) first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s C4 Therapeutics position peaked at $268K in Q1 2022.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.